New research published today, , in the New England Journal of Medicine details promising results for a combination therapy in the treatment of HER2-positive metastatic breast cancer. The study investigates the efficacy of trastuzumab deruxtecan, when added to the standard treatment of pertuzumab, in patients whose cancer has spread.
Understanding HER2-Positive Breast Cancer
Breast cancer is not a single disease. Different types are classified based on the characteristics of the cancer cells. HER2-positive breast cancer means that the cancer cells have a higher-than-normal level of a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes cancer cell growth. Approximately 20% of breast cancers are HER2-positive. These cancers tend to be more aggressive, but they are also more responsive to targeted therapies designed to block the HER2 protein.
Current Treatment Landscape
Standard treatment for HER2-positive metastatic breast cancer typically involves a combination of drugs, including trastuzumab (Herceptin) and pertuzumab (Perjeta), often alongside chemotherapy. While these treatments have significantly improved outcomes, many patients eventually develop resistance, leading to disease progression. This highlights the need for new and more effective therapeutic options.
The New Study: Trastuzumab Deruxtecan and Pertuzumab
The recent study focused on evaluating trastuzumab deruxtecan (Enhertu) in combination with pertuzumab. Trastuzumab deruxtecan is a newer targeted therapy that delivers a potent chemotherapy drug directly to cancer cells expressing HER2. This targeted delivery aims to maximize effectiveness while minimizing damage to healthy cells.
The research, published in Volume 394, Issue 9 of the New England Journal of Medicine, provides data on the use of this combination. The specifics of the study design, patient population, and detailed results are available in the full publication.
Implications for Patients
The findings from this study offer a potential new avenue for treating patients with HER2-positive metastatic breast cancer who have progressed on previous therapies. The addition of trastuzumab deruxtecan to pertuzumab may offer improved disease control and potentially extend survival. However, it’s important to remember that Here’s a single study, and further research is needed to confirm these findings and determine the optimal use of this combination therapy.
Potential Side Effects and Considerations
As with any cancer treatment, trastuzumab deruxtecan and pertuzumab can cause side effects. The New England Journal of Medicine publication will contain detailed information regarding the observed side effects in the study population. Patients considering this treatment should discuss the potential benefits and risks with their oncologist to make an informed decision. This proves crucial to have a thorough understanding of the possible side effects and how they can be managed.
Looking Ahead
The publication of this research in a leading medical journal like the New England Journal of Medicine signifies a significant step forward in the treatment of HER2-positive metastatic breast cancer. Ongoing research will continue to refine treatment strategies and improve outcomes for patients facing this challenging disease. The journal’s website (https://www.nejm.org/) provides access to the latest research and review articles in the field of medicine, including previous issues dating back to 1960. Specifically, the 2026 issues are browsable at https://www.ovid.com/journals/nejm/issues/2026.
Another study published in the same issue of the New England Journal of Medicine, , investigated the reduction of antihypertensive treatment in nursing home residents. This separate research highlights the importance of individualized care and careful medication management in vulnerable populations.
